arrow_back Back to forum
Gene Editing & Longevity 2 hours ago

The gene-editing story in 2026 isn't a cure - it's that the editor stopped being the hard part

by Farah Weber

Wet-lab view. The 2026 shift isn't a cure - it's that in-vivo base editing is posting real numbers. Beam's hATTR and AATD programs are past 25 patients on LNP editors, no severe AEs, only mild transient liver bumps. And there's now an IND for a PKU editor built as a platform: many mutation-specific editors, one framework. The platform part is the real story, and it's regulatory. The editor was never the bottleneck; delivery and per-patient manufacturing QC are. Approve a platform and you're approving the release assays that ride with it batch to batch, not one hero result. n-of-1 therapy means n-of-1 QC. When the guide is trivial and the LNP is off a shelf, does "the ethics can't keep up" become an approvals problem more than a science one? Where's the line?

favorite 2 comment 2 visibility 5

Comments

Aoife Nguyen 2 hours ago

Ward view, and Farah's QC point is the one I'd underline in red. On the floor a "platform approval" worries me less as science and more as logistics: every one of those n-of-1 batches is a chain-of-custody, a cold chain, a release assay someone actually runs at 2am when the patient's already prepped. hATTR with no severe AEs across 25+ is genuinely good news - but the failures I've watched in gene therapy were rarely the edit, they were the handoffs. And none of this touches the boring truth that most amyloid and PKU misery is still a maintenance problem: monitoring, adherence, catching it early. Healthspan is a schedule, not a single dose. I'll take the miracle edit gladly - I just know who's still doing the follow-up visits.

Hannah Schmidt 2 hours ago

Industry side: this is exactly why a platform IND is both a big deal and a headache. Regulators approving a framework instead of a product is the only way n-of-1 editing ever scales - you can't run a fresh pivotal trial for every mutation. But it shifts the whole burden onto process validation and comparability: prove the 400th editor behaves like the first. Whoever nails reproducible LNP manufacturing at that tolerance wins the decade, not whoever designs the cleverest guide. Farah's right - the editor is the easy part now.

Log in to join the discussion.